Changes in XVIVO Perfusion’s Management Team
XVIVO Perfusion AB (publ) (“XVIVO”) today announces that the company's CFO Christoffer Rosenblad has been appointed to a newly established position as Chief Operating Officer, COO. Kristoffer Nordström, XVIVO's current Financial Manager, will be appointed to the position as CFO. The changes will take effect on December 1, 2020 and Christoffer Rosenblad will remain as Vice President with responsibility for Investor Relations
The establishment of a new position of COO is part of the initiative to strengthen XVIVO's management team, which began on September 4, 2020, in connection with the appointment of a new Commercial Director and a new Research and Development Director.
"During Christoffer's eight years as CFO, XVIVO has maintained a strong focus on profitability and growth," says Dag Andersson, CEO of XVIVO, in a comment on the appointment.
"It is a natural step for Christoffer to take on new challenges and take on a more operational role in the company."
Kristoffer Nordström has been employed at XVIVO for three years and previous to that has 10 years of experience as an authorized public accountant at KPMG.
"During his time at XVIVO, Kristoffer has been responsible for several of the tasks belonging to a CFO in a listed company," CEO Dag Andersson states. "For this reason, he is ready to completely take on the role of CFO."
The establishment of a new position of COO is a part of the decided reorganization which affects all of the company's departments and aims to create a more efficient and purposeful business. The cost of the reorganization is reported during the third quarter of 2020 and is estimated to affect EBITDA negatively by SEK 5.0 million.
"With this reorganization, we have laid the foundation required to strengthen and develop our world-leading position in organ transplantation and deliver according to our strategy," Dag Andersson says.
Gothenburg, September 21, 2020
Dag Andersson
For further information please contact:
Christoffer Rosenblad, CFO, +46 73 519 21 59 e-post: christoffer.rosenblad@xvivoperfusion.com
Dag Andersson, CEO, +46 76 643 30 31, e-post: dag.andersson@xvivoperfusion.com
About Us
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.
